Abstract Listings 2024

Purpose

The objective of this study was to evaluate the utilization, safety and effectiveness of sonidegib for the treatment of periocular locally advanced basal cell carcinoma (laBCC) in a real-world setting

Methods

This observational study included patients treated with sonidegib for laBCC. Adjustments to dosage were made based on patient tolerance and clinical condition. The study monitored adverse events (AEs), dosage adjustments, and treatment outcomes.

Results

Twelve patients (four females and eight males) with periocular laBCC, aged between 67 and 92 years (average age 83.25 years, median age 86 years), were enrolled in the study. Eight patients (66.67%) completed the initial 6-month protocol, while others required dosage adjustments due to AEs. Muscle spasms were the most common AE (41.67%), followed by weight loss, fatigue, and dysgeusia (25%), alopecia, and nausea (16.67%). Two patients (16.67%) developed severe anemia, necessitating treatment discontinuation. One patient died from other comorbidities. The average follow-up time was 30.75 months. At the time of result collection, seven patients (58.33%) achieved CR, one patient (8.33%) had SD and later underwent surgery, and four patients (33.33%) had PR.

Conclusion

Sonidegib is a safe and effective treatment option for periocular laBCC, even in an elderly population with multiple comorbidities. Dosage adjustments were well-tolerated and necessary to manage AEs. The high rate of response to treatment suggests that sonidegib can be a viable alternative when surgery is not feasible.

Additional Authors

↑ Back to top